A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)

2014 ◽  
Vol 50 (1) ◽  
pp. 23-30 ◽  
Author(s):  
C. Delbaldo ◽  
D. Serin ◽  
M. Mousseau ◽  
S. Greget ◽  
B. Audhuy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Randomised Trial ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Positive Breast Cancer

Gruppo Oncologico Nord Ovest – Mammella Intergruppo (GONO MIG)

2006 ◽  
Vol 9 (S1) ◽  
pp. 212-222
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Randomized Study ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Positive ◽  
Positive Breast Cancer

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Gruppo Oncologico Nord Ovest – Mammella Intergruppo (GONO MIG). Clinical trials include: Standard CEF versus accelerated CEF as adjuvant chemotherapy in node-positive or high-risk node-negative (T > 2 cm, age <35 years, G3, negative hormone receptors or high TL1 or S-phase) breast cancer. A phase III randomized trial. MIG-1Epirubicin plus paclitaxel versus cyclophosphamide, epirubicin and 5-fluorouracil as adjuvant chemotherapy in node-positive breast cancer patients. A phase III randomized study. MIG-5A phase III randomized study of sequential epidoxorubicin plus cyclophosp-amide followed by docetaxel (EC D) versus a combination of 5-fluorouracil, epidoxorubicin and cyclophosp-amide (FEC) as adjuvant treatment of node-negative early breast cancer patients.A phase III randomized study of EC followed by paclitaxel versus FEC followed by paclitaxel, all given either every 3 or 2 weeks supported by pegfilgrastim, for node-positive breast cancer patients.Prevention of chemotherapy-induced menopause by temporary ovarian suppression with triptorelin versus control in young breast cancer patients. A randomized phase III multicenter study.Letrozole adjuvant therapy duration (lead) study: standard versus long treatment. A phase III trial in post-menopausal women with early breast cancer.

Dye-guided sentinel lymphadenectomy in clinically node-negative and node-positive breast cancer patients

Breast Cancer ◽  
1998 ◽  
Vol 5 (4) ◽  
pp. 381-387 ◽  
Author(s):  
Masakuni Noguchi ◽  
Koichiro Tsugawa ◽  
Futoshi Kawahara ◽  
Etsuro Bando ◽  
Koichi Miwa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Sentinel Lymphadenectomy ◽  
Node Positive ◽  
Positive Breast Cancer

Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients

2017 ◽  
Vol 213 (4) ◽  
pp. 810-813 ◽  
Author(s):  
Brittany L. Murphy ◽  
Tanya L. Hoskin ◽  
Judy C. Boughey ◽  
Amy C. Degnim ◽  
James W. Jakub ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Nipple Sparing Mastectomy ◽  
Nipple Sparing ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document